SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The sharp rally has no confirmed company-news catalyst; traders are focused on anticipation of the REGAL Phase 3 final analysis, which is triggered at 80 survival events after the last disclosed count of 78. Some interpret the CEOs anniversary message and SELLASs planned ASH presence as signs of a potential buyout, while others call that speculation and see the move as a rebound or possible short covering.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about competition and a prolonged share-price decline. Many expect further weakness, while bulls argue pessimism is already priced in and see room for a rebound if results or the outlook are stronger than feared.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is drawing attention as traders position around the full Phase 3 melanoma results for its personalized cancer vaccine, intismeran, with Merck; the prior positive topline result has fueled a sharp rally. Bulls see validation of a broader oncology platform, while skeptics warn that expectations and valuation are stretched and debate a possible sell-the-news reaction.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound is being attributed by traders to possible short covering and anticipation of upcoming DM1 and FSHD siRNA data, with Arrowheads RNAi results cited as supportive context. No new Sarepta catalyst is confirmed in the discussion, and some traders view the move as technical or part of broader biotech strength.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is drawing attention amid a steep selloff in AI-data-center and neocloud stocks, as traders debate financing risks and whether sector-wide concerns apply to the company. Co-CEO Daniel Roberts comments that data centers were built with cash and customer prepayments help fund GPU costs have reassured some bulls, while others remain concerned about dilution, execution and IRENs weak performance versus peers.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings beat and new share-repurchase authorization are being overshadowed by a narrowed full-year profit outlook whose midpoint was unchanged, prompting a sharp selloff. Traders are split between viewing the buyback and stronger cash-flow outlook as support and seeing cautious guidance, lower U.S. sales, and cost pressures as reasons for the decline.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solanas volatile pullback and bounce amid broader crypto weakness are driving discussion, with traders watching support and Bitcoins direction. Dip-buyers are accumulating and staking, while bearish traders warn the recovery may fail and expect further downside.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA is drawing attention ahead of its Q3 earnings report, with traders watching whether ASCENIVs growth can offset continued weakness in BIVIGAM and restore confidence in the companys outlook. Some point to improving share-price momentum and buybacks, while others remain cautious because of the earlier short-seller allegations and questions about growth visibility.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal testing business to Labcorp is driving the sharp rally, with traders viewing the cash transaction as a potential balance-sheet and strategic reset. Bulls welcome the deal and momentum, while skeptics argue the sale removes a revenue-generating business and leaves concerns about declining operations and debt; the transaction remains subject to approval.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

A sharp post-earnings selloff, despite a quarterly beat, has put Intuitive Surgicals growth outlook in focus: traders cite slower U.S. da Vinci procedure growth and guidance that did not improve, alongside valuation concerns. The community is split between buying the pullback on the companys robotic-surgery moat and recurring revenue, and waiting amid worries about competition and further growth deceleration.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?

Equity

Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.


Direxion Shares ETF Trust - Direxion Daily Pharmaceutical & Medical Bull 3X ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Eli Lilly announced it will pay $6.75 per share in cash, with additional milestone payments tied to the development of ATAI's two lead depression therapies.</li><li>The pharma giant said the acquisition strengthens its neuroscience pipeline with two late-stage programs targeting treatment-resistant depression.</li><li>Over the past year, Compass has significantly outperformed ATAI.</li></ul>Shares of AtaiBeckley Inc. (ATAI) and Compass Pathways (CMPS) surged in pre-market trade on Thursday, and both were among the top-trending tickers on Stockwits after Eli Lilly (LLY) confirmed it is acquiring AtaiBeckley.Lilly stated it will acquire all outstanding ATAI shares for $6.75 per share in cash at closing, plus up to $2.50 per share tied to future development and regulatory milestones for ATAI's two lead programs, bringing total potential value to as much as $9.25 per share.&nbsp;Based on ATAI's Wednesday close of around $5.36, the $6.75 per share cash offer represents a premium of approximately 25.9%. Taking total potential consideration of $9.25 into account, the premium to Wednesday's close would be approximately 72.6%.The deal is expected to close in the third quarter (Q3), pending shareholder and regulatory approval.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/ATAI_2026_07_16_06_37_17_png_4cad859a33.webp" alt="ATAI_2026-07-16_06-37-17.png" width="2643" height="1588"><figcaption>ATAI stock historical performance vs. pre-market on July 16. | Source: TradingView</figcaption></figure><a href="https://stocktwits.com/symbol/ATAI/">ATAI stock</a> jumped over 33% in pre-market trade, paring gains from a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-atai-stock-soaring-59-after-hours/cZZPl7dR7rk">jump of around 60%</a> earlier in the day. If pre-market grains hold, ATAI’s stock is on track to hit its highest levels since December 2021 and mark the biggest single-day jump in the company’s history.<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260716_063534529_png_3a8bd239cd.webp" alt="koyfin_20260716_063534529.png" width="2400" height="1240"><figcaption>ATAI stock historical single-day stock price changes. | Source: Koyfin</figcaption></figure><a href="https://stocktwits.com/symbol/LLY">LLY's stock</a> was also among the top trending tickers on Stocktwits, edging higher by around 0.4% in pre-market trade.<h2 class="st-heading-2">What is Lilly Buying?</h2>ATAI's lead asset is BPL-003, an intranasal, synthetic form of 5-MeO-DMT for treatment-resistant depression that has already earned FDA Breakthrough Therapy Designation and entered Phase 3 activities, following a Phase 2b study showing rapid and durable symptom reduction after a roughly two-hour in-clinic session.&nbsp;Its second program, VLS-01, is a buccal film formulation of DMT currently in Phase 2b. "Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," said Carole Ho, Lilly Neuroscience's president.&nbsp;ATAI co-founder and CEO Srinivas Rao said the deal gives the company's pipeline "the resources and scale" to move faster than it could independently.<h2 class="st-heading-2">Why Is CMPS Stock Rallying Too?</h2><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> gained more than 7% in pre-market trade, and the move isn't purely coincidental. ATAI has historically been Compass's largest shareholder, though its stake has fallen from a peak of roughly 29% to 4.96% as of a February 2026 filing, dropping it below the 5% threshold requiring continued disclosure of its position.CMPS shares are also riding a separate, broader tailwind. Regulatory momentum for psychedelic therapies has been building steadily since President Donald Trump signed an executive order in April directing the Federal Drug Administration (FDA) to fast-track review of psychedelic drugs with Breakthrough Therapy designation.&nbsp;Earlier this week, the FDA announced a public hearing on psychedelic therapies and published final clinical guidance for developers on July 14. The Department of Health and Human Services (HHS) and the Department of Veterans Affairs also announced a new collaboration in anticipation of the first investigational drug approvals.&nbsp;<h2 class="st-heading-2">How Does Retail Feel About AtaiBeckley-Eli Lilly Deal?</h2>Retail sentiment around ATAI stock on Stocktwits rose to ‘extremely bullish’ from ‘bullish’ territory over the past day. Chatter stayed at ‘extremely high’ levels. Meanwhile, sentiment around CMPS stock fell to ‘neutral’ from ‘bullish’ territory, accompanied by chatter at ‘high’ levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_07_16_072103_png_95d0276b5f.webp" alt="Screenshot 2026-07-16 072103.png" width="1272" height="690"><figcaption>ATAI stock retail sentiment on July 16 as of 7:30 a.m. ET | Source: Stocktwits&nbsp;</figcaption></figure>Retail traders on the platform expressed excitement about what the takeover could mean for AtaiBeckley’s future growth.<stembedurl>https://www.stocktwits.com/LoadedUP1000/message/659184838</stembedurl><h2 class="st-heading-2">Comparing The Fundamentals</h2>The two companies sit at different stages of development. ATAI’s stock carries a ‘Strong Buy’ rating from two analysts, and a ‘Buy’ rating from 12 out of the 14 analysts covering the stock, according to Koyfin data. The average price target for the shares is around $14.17, and a trailing one-year return of about 102%.Wall Street was similarly bullish on Compass as well. CMPS Stock carries a ‘Strong Buy’ rating from three analysts and a ‘Buy’ rating from 12 out of the 15 analysts covering the stock. The average price target for the shares is around $24.47, implying a roughly 84% potential upside from Wednesday's close.Neither company currently generates meaningful revenue. Compass has posted essentially $0 in quarterly sales across every quarter tracked since early 2025, reflecting its status as a clinical-stage company with no approved products yet. Consensus estimates project continued losses, including a projected adjusted loss of $0.31 per share for the quarter ending June 30.&nbsp;ATAI shows a similar profile, with quarterly sales in the range of just $0 to $2 million and a projected adjusted loss of $0.11 per share for the same period.Over the past year, Compass has significantly outpaced ATAI since mid-April, gaining nearly 93% year-to-date versus ATAI's roughly 31%<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260716_061620094_png_c1a394bb97.webp" alt="koyfin_20260716_061620094.png" width="2400" height="1240"><figcaption>CMPS stock vs. ATAI stock performance year-to-date. | Source: Koyfin</figcaption></figure>Unlike ATAI, which will now become part of Eli Lilly, Compass remains an independent, publicly traded company focused on developing psychedelic therapies for treatment-resistant mental health conditions.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-says-53-b-offer-for-pay-pal-is-simply-too-low/cZZPR3LR7Ai">Michael Burry Says $53B Offer For PayPal Is 'Simply Too Low' – ‘The Big Short’ Investor Expects Higher Bid</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Eli Lilly logo on modern glass office building facade with partly cloudy sky, South San Francisco, California, October 16, 2025. (Photo by Smith Collection/Gado/Getty Images)

Shares of AtaiBeckley Inc. (ATAI) and Compass Pathways (CMPS) surged in pre-market trade on Thursday, and both were among the top-trending tickers on Stockwits after Eli Lilly (LLY) confirmed it is acquiring AtaiBeckley.

AtaiBeckley Inc.

COMPASS Pathways

Lilly(Eli) & Co

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

AdvisorShares Psychedelics ETF

SPDR Pharmaceuticals ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Feed

News

Sentiment

Fundamentals

Info

PILL News